Holen Sie sich die Stockscreener-App
37.35
1.68%
0.55
Handel nachbörslich:
37.35
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
New orexin data on narcolepsy, schizophrenia at ASCP meeting - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: Unlocking Potential With A 23.47% Upside - DirectorsTalk Interviews
Alkermes showcases data from psychiatry portfolio and sleep research into real world patient experience at spring 2026 scientific conferences - MSN
Alkermes (ALKS) director logs RSU exercise, tax withholding and new equity grants - Stock Titan
Alkermes (ALKS) director gets new RSUs, options and tax withholding - Stock Titan
[Form 4] Alkermes plc. Insider Trading Activity - Stock Titan
Alkermes (NASDAQ: ALKS) director reports RSU vesting, option grant and tax-share withholding - Stock Titan
[Form 4/A] Alkermes plc. Amended Insider Trading Activity - Stock Titan
Alkermes (ALKS) director receives equity awards and corrects vesting terms - Stock Titan
Alkermes (ALKS) director reports RSU vesting, tax withholding and new stock options - Stock Titan
Alkermes (NASDAQ: ALKS) director logs RSU exercise, new option and RSU grants - Stock Titan
Avoiding Lag: Real-Time Signals in (ALKS) Movement - Stock Traders Daily
Alkermes Shareholders Approve Amended Stock Incentive Plan - The Globe and Mail
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences - Yahoo Finance
Alkermes (ALKS) shareholders approve 2018 equity plan, directors and auditor - Stock Titan
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge - TipRanks
Alkermes plc (ALKS) Stock Analysis: Uncovering a 21% Upside Potential in Biopharmaceutical Innovation - DirectorsTalk Interviews
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises - MSN
Alkermes plc stock (IE00B56GVS15): M&A deal with Avadel and fresh analyst signals put focus on futur - AD HOC NEWS
Alkermes plc stock (IE00B56GVS15): focus shifts after oncology spin-off and latest quarterly figures - AD HOC NEWS
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline - TipRanks
T. Rowe Price (NASDAQ: ALKS) holds 4.66M shares, 2.8% stake - Stock Titan
Alkermes Reports Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia - Sleep Review
What is HC Wainwright's Estimate for Alkermes Q2 Earnings? - MarketBeat
Alkermes plc $ALKS Shares Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Alkermes stock hits 52-week high at $38.94 By Investing.com - Investing.com South Africa
Alkermes plc stock (IE00B56GVS15): Baird raises price target to $48 - AD HOC NEWS
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Alkermes reports encouraging data from Phase III study of Lumryz - Clinical Trials Arena
Alkermes stock hits 52-week high at $38.94 - Investing.com
ALKS Maintained by Baird -- Price Target Raised to $48.00 - GuruFocus
Alkermes (NASDAQ:ALKS) Price Target Raised to $48.00 - MarketBeat
Alkermes Gains Strength On Strong Execution And Strategic Diversification - RTTNews
Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH - Citeline News & Insights
Alkermes Earnings Surprise Keeps Nasdaq Composite Watching - Kalkine Media
Alkermes posts late-stage trial win for Lumryz in new sleep disorder - MSN
Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings - simplywall.st
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles - Benzinga
Investors Can Find Comfort In Alkermes' (NASDAQ:ALKS) Earnings Quality - 富途牛牛
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023 - Quantisnow
Positive Phase 3 Results for Alkermes (ALKS) LUMRYZ in Treating Hypersomnia - GuruFocus
Alkermes (ALKS) Shares Rise on Positive Sleep Disorder Therapy T - GuruFocus
Alkermes stock maintains Buy rating on positive sleep disorder trial By Investing.com - Investing.com South Africa
Alkermes stock maintains Buy rating on positive sleep disorder trial - Investing.com
Alkermes reports positive phase 3 trial results for LUMRYZ - Investing.com UK
Alkermes Announces Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia, Plans FDA Submission by End of 2026 - Minichart
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia - BioSpace
Alkermes Reports Positive Phase 3 Results for LUMRYZ - TipRanks
Alkermes reports positive phase 3 trial results for LUMRYZ By Investing.com - Investing.com South Africa
Alkermes Announces Positive Phase 3 REVITALYZ Results for LUMRYZ, Plans sNDA Filing by End of 2026 - TradingView
Alkermes (Nasdaq: ALKS) reports strong phase 3 LUMRYZ results in idiopathic hypersomnia - Stock Titan
5.13%
6.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):